EcoDrugPlus

26s Proteasome Non-Atpase Regulatory Subunit 11

Ensembl ID : ENSCHAG00000007627
Gene Symbol: LOC105908963
3 Cross references
153 Possible Orthologues:

26s Proteasome Non-Atpase Regulatory Subunit 11b

Ensembl ID : ENSCHAG00000019372
Gene Symbol: LOC105888866
3 Cross references
214 Possible Orthologues:

26s Proteasome Non-Atpase Regulatory Subunit 4-Like

Ensembl ID : ENSCHAG00000020415
Gene Symbol: LOC105901691
3 Cross references
221 Possible Orthologues:

3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2-Like

Ensembl ID : ENSCHAG00000001588
Gene Symbol: LOC105911574
3 Cross references
192 Possible Orthologues:

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSCHAG00000012143
Gene Symbol: PDPK1
3 Cross references
222 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase B

Ensembl ID : ENSCHAG00000024377
Gene Symbol: HPDB
1 Cross references
207 Possible Orthologues:

40s Ribosomal Protein S5

Ensembl ID : ENSCHAG00000015626
Gene Symbol: LOC105903695
3 Cross references
246 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSCHAG00000016354
Gene Symbol: NT5E
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSCHAG00000021757
Gene Symbol: HTR2B
1 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSCHAG00000010715
Gene Symbol: HTR2CL1
1 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSCHAG00000006310
Gene Symbol: HTR5AB
1 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSCHAG00000016315
Gene Symbol: HTR1B
3 Cross references
178 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).